Quantitative Subharmonic Breast Imaging
Condition: Breast Cancer
Intervention: 3D HI and SHI of UCA
Intervention description: Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
Phase: Phase 4
Study type: Interventional
Primary purpose: Diagnostic
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 219.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No
Keywords: breast abnormality; ultrasound imaging; ultrasound contrast agent; subharmonic imaging

Summary:

      This is a non-randomized trial of 450 women with a breast abnormality, who are scheduled for
      a breast biopsy of this abnormality. The study will be conducted at two clinical sites. The
      primary objective of this trial is:

      To evaluate if quantitative 3D Subharmonic imaging (SHI) or pulse inversion harmonic imaging
      (HI) can improve the characterization of benign and malignant breast masses (independently or
      in combination with other imaging modes) compared to x-ray mammography, fundamental grayscale
      ultrasound (US) or power Doppler imaging (PDI).

      The secondary aim of this trial is:

      To compare quantitative (bifurcations & vessel length) and semi-quantitative (blood pool &
      parametric imaging) measures of the vascular morphology of breast lesions determined by
      pathology and by SHI.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Be a female diagnosed by x-ray mammography (performed within 90 days prior to the
             study procedure) as having a solid breast mass or abnormal area without a mass.

          -  Be scheduled for a biopsy (core / excisional / lumpectomy) of the mass or region of
             abnormality or for mastectomy within 30 days after this study procedure.

          -  Be at least 18 years of age.

          -  Be medically stable.

          -  If a female of child-bearing potential, must have a negative pregnancy test.

          -  Have signed Informed Consent to participate in the study.

        Exclusion Criteria:

          -  Males

          -  Females who are pregnant or nursing.

          -  Patients whose breast lesion is unequivocally a cyst by unenhanced US.

          -  Patients currently on chemotherapy or with other primary cancers requiring systemic
             treatment.

          -  Patients who are medically unstable, patients who are seriously or terminally ill, and
             patients whose clinical course is unpredictable. For example:

          -  Patients on life support or in a critical care unit.

          -  Patients with unstable occlusive disease (eg, crescendo angina)

          -  Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular
             tachycardia.

          -  Patients with uncontrolled congestive heart failure (NYHA Class IV)

          -  Patients with recent cerebral hemorrhage.

          -  Patients with clinically significant and unstable renal and/or liver disease (eg,
             transplant recipients in rejection)

          -  Patients who have undergone surgery within 24 hours prior to the study sonographic
             examination.

          -  Patients with known hypersensitivity to perflutren

          -  Patients who have received any contrast medium (X-ray, MRI, CT, of US) in the 24 hours
             prior to the research US exam

          -  Patients with cardiac shunts.

          -  Patients with congenital heart defects.

          -  Patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary
             emboli.

          -  Patients with confirmed or suspected liver lesions.

          -  Patients with respiratory distress syndrome.

          -  Patients who have had excisional biopsy/lumpectomy of the current area of interest
             within the past 6 weeks.